Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2016

Open Access 01-12-2016 | Review

Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review

Authors: Bipin Adhikari, Nicola James, Gretchen Newby, Lorenz von Seidlein, Nicholas J. White, Nicholas P. J. Day, Arjen M. Dondorp, Christopher Pell, Phaik Yeong Cheah

Published in: Malaria Journal | Issue 1/2016

Login to get access

Abstract

Background

Mass anti-malarial administration has been proposed as a key component of the malaria elimination strategy in South East Asia. The success of this approach depends on the local malaria epidemiology, nature of the anti-malarial regimen and population coverage. Community engagement is used to promote population coverage but little research has systematically analysed its impact. This systematic review examines population coverage and community engagement in programmes of mass anti-malarial drug administration.

Methods

This review builds on a previous review that identified 3049 articles describing mass anti-malarial administrations published between 1913 and 2011. Further search and application of a set of criteria conducted in the current review resulted in 51 articles that were retained for analysis. These 51 papers described the population coverage and/or community engagement in mass anti-malarial administrations. Population coverage was quantitatively assessed and a thematic analysis was conducted on the community engagement activities.

Results

The studies were conducted in 26 countries: in diverse healthcare and social contexts where various anti-malarial regimens under varied study designs were administered. Twenty-eight articles reported only population coverage; 12 described only community engagement activities; and 11 community engagement and population coverage. Average population coverage was 83% but methods of calculating coverage were frequently unclear or inconsistent. Community engagement activities included providing health education and incentives, using community structures (e.g. existing hierarchies or health infrastructure), mobilizing human resources, and collaborating with government at some level (e.g. ministries of health). Community engagement was often a process involving various activities throughout the duration of the intervention.

Conclusion

The mean population coverage was over 80% but incomplete reporting of calculation methods limits conclusions and comparisons between studies. Various community engagement activities and approaches were described, but many articles contained limited or no details. Other factors relevant to population coverage, such as the social, cultural and study context were scarcely reported. Further research is needed to understand the factors that influence population coverage and adherence in mass anti-malarial administrations and the role community engagement activities and approaches play in satisfactory participation.
Appendix
Available only for authorised users
Literature
1.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRefPubMedPubMedCentral
2.
Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520:683–7.CrossRefPubMedPubMedCentral
3.
4.
5.
von Seidlein L, Dondorp A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti Infect Ther. 2015;13:715–30.CrossRef
6.
Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93:125–34.CrossRefPubMedPubMedCentral
7.
von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003;19:452–60.CrossRef
8.
Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, et al. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province. China. Malar J. 2013;12:383.CrossRefPubMed
9.
De Martin S, von Seidlein L, Deen JL, Pinder M, Walraven G, Greenwood B. Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Trop Med Int Health. 2001;6:442–8.CrossRefPubMed
10.
Dial NJ, Ceesay SJ, Gosling RD, D’Alessandro U, Baltzell KA. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J. 2014;13:47.CrossRefPubMedPubMedCentral
11.
Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, et al. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PLoS ONE. 2012;7:e37166.CrossRefPubMedPubMedCentral
12.
Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J. 2011;10:247.CrossRefPubMedPubMedCentral
13.
14.
Kaneko A. A community-directed strategy for sustainable malaria elimination on islands: short-term MDA integrated with ITNs and robust surveillance. Acta Trop. 2010;114:177–83.CrossRefPubMed
15.
16.
Cantey PT, Rout J, Rao G, Williamson J, Fox LM. Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis. 2010;4:e728.CrossRefPubMedPubMedCentral
17.
Cheah PY, White NJ. Antimalarial mass drug administration: ethical considerations. Int Health. 2016;8:235–8.CrossRefPubMed
18.
Tindana PO, Singh JA, Tracy CS, Upshur RE, Daar AS, Singer PA, et al. Grand challenges in global health: community engagement in research in developing countries. PLoS Med. 2007;4:e273.CrossRefPubMedPubMedCentral
19.
CTSA. Clinical and translational science awards consortium. Principles of community engagement. 2nd ed. NIH Publication No 11-7782. 2011.
20.
Atkinson JA, Vallely A, Fitzgerald L, Whittaker M, Tanner M. The architecture and effect of participation: a systematic review of community participation for communicable disease control and elimination. Implications for malaria elimination. Malar J. 2011;10:225.CrossRefPubMedPubMedCentral
21.
WHO special programme for research and training in tropical diseases. Community-directed interventions for major health problems in Africa: a multi-country study: final report. Geneva: World Health Organization; 2008.
22.
CDI Study Group. Community-directed interventions for priority health problems in Africa: results of a multicountry study. Bull World Health Organ. 2010;88:509–18.CrossRef
23.
Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;12:CD008846.
24.
Dola SK. Mass drug administration as a supplementary attack measure in malaria eradication programme. East Afr Med J. 1974;51:529–31.PubMed
25.
Lwin KM, Imwong M, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K, et al. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar J. 2015;14:319.CrossRefPubMedPubMedCentral
26.
Berberian DA, Dennis EW. Field experiments with chloroquine diphosphate. Am J Trop Med Hyg. 1948;28:755–76.PubMed
27.
Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet. 1983;2:500–3.CrossRefPubMed
28.
Gribben G. Mass treatment with plasmoquine. BMJ. 1933;3802:919–20.
29.
Handerson LH. Prophylaxis of malaria in the Sudan, with special reference to the use of plasmoquine. Trans R Soc Trop Med Hyg. 1934;28:157–64.CrossRef
30.
Garfield RM, Vermund SH. Health education and community participation in mass drug administration for malaria in Nicaragua. Soc Sci Med. 1986;22:869–77.CrossRefPubMed
31.
Pribadi W, Muzaham F, Santoso T, Rasidi R, Rukmono B. The implementation of community participation in the control of malaria in rural Tanjung Pinang, Indonesia. Southeast Asian J Trop Med Public Health. 1986;17:371–8.PubMed
32.
Clyde DF. Malaria control in Tanganyika under the German administration. I. E. East Afr Med J. 1961;38:27–42.
33.
Charles LJ, Van Der Kaay HJ, Vincke IH, Brady J. The appearance of pyrimethamine resistance in Plasmodium falciparum following self-medication by a rural community in Ghana. Bull World Health Organ. 1962;26:103–8.PubMedPubMedCentral
34.
Baukapur SN, Babu CJ. A focal outbreak of malaria in Valsad district, Gujarat state. J Commun Dis. 1984;16:268–72.PubMed
35.
Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet. 2000;356:1560–4.CrossRefPubMed
36.
Butler FA. Malaria control program on a South Pacific base. US Nav Med Bull. 1943;41:1603–12.
37.
Sehgal JK. Progress of malaria eradication in Orissa State during 1965–1966. Bull Ind Soc Mal Com Dis. 1968;5:88–93.
38.
Dapeng L, Leyuan S, Xili L, Xiance Y. A successful control programme for falciparum malaria in Xinyang, China. Trans R Soc Trop Med Hyg. 1996;90:100–2.CrossRefPubMed
39.
Gabaldon A, Guerrero L. An attempt to eradicate malaria by the weekly administration of pyrimethamine in areas of out-of-doors transmission in Venezuela. Am J Trop Med Hyg. 1959;8:433–9.PubMed
40.
Roberts JM. The control of epidemic malaria in the highlands of Western Kenya. I. Before the campaign. J Trop Med Hyg. 1964;67:161–8.PubMed
41.
Cheah PY, Lwin KM, Phaiphun L, Maelankiri L, Parker M, Day NP, et al. Community engagement on the Thai–Burmese border: rationale, experience and lessons learnt. Int Health. 2010;2:123–9.CrossRefPubMedPubMedCentral
42.
von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg. 2003;97:217–25.CrossRef
43.
Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin–piperaquine. Malar J. 2010;9:57.CrossRefPubMedPubMedCentral
44.
Doi H, Kaneko A, Panjaitan W, Ishii A. Chemotherapeutic malaria control operation by single dose of fandisar plus primaquine in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health. 1989;20:341–9.PubMed
45.
Archibald HM. Field trials of mass administration of antimalarial drugs in northern Nigeria. World Health Organization; 1960. WHO/MAL/262–11.
46.
Clyde DF. Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. Bull World Health Organ. 1962;27:203–12.PubMedPubMedCentral
47.
MacCormack CP, Lwihula G. Failure to participate in a malaria chemo suppression programme: North Mara, Tanzania. J Trop Med Hyg. 1983;86:99–107.PubMed
48.
Kaseje DC, Sempebwa EK. An integrated rural health project in Saradidi, Kenya. Soc Sci Med. 1989;28:1063–71.CrossRefPubMed
49.
Head BW. Community Engagement: participation on Whose Terms? Aust J Political Sci. 2007;42:441–54.CrossRef
50.
Rifkin SB. Paradigms lost: toward a new understanding of community participation in health programmes. Acta Trop. 1996;61:79–92.CrossRefPubMed
51.
Greenough P. Intimidation, coercion and resistance in the final stages of the South Asian smallpox eradication campaign, 1973–1975. Soc Sci Med. 1995;41:633–45.CrossRefPubMed
52.
Rieckmann KH. The chequered history of malaria control: are new and better tools the ultimate answer? Ann Trop Med Parasitol. 2006;100:647–62.CrossRefPubMed
53.
Purdey AF, Adhikari GB, Robinson SA, Cox PW. Participatory health development in rural Nepal: clarifying the process of community empowerment. Health Educ Q. 1994;21:329–43.CrossRefPubMed
54.
Aregawi M, Smith SJ, Sillah-Kanu M, Seppeh J, Kamara AR, Williams RO, et al. Impact of the mass drug administration for malaria in response to the Ebola outbreak in Sierra Leone. Malar J. 2016;15:480.CrossRefPubMedPubMedCentral
55.
Kuehne A, Tiffany A, Lasry E, Janssens M, Besse C, Okonta C, et al. Impact and lessons learned from mass drug administrations of malaria chemoprevention during the Ebola Outbreak in Monrovia, Liberia, 2014. PLoS ONE. 2016;11:e0161311.CrossRefPubMedPubMedCentral
56.
57.
Lavery JV. Putting international research ethics guidelines to work for the benefit of developing countries. Yale J Health Policy Law Ethics. 2004;4:319–36.PubMed
58.
Kingsbury AN, Amies CR. A field experiment on the value of plasmoquine in the prophylaxis of malaria. Trans R Soc Trop Med Hyg. 1931;25:159–72.CrossRef
59.
Kligler IJ, Mer G. Periodic intermittent treatment with chinoplasmine as a measure of malaria control in a hyperendemic area. Riv Malariol. 1931;10:425–38.
60.
White RS, Adhikari AK. Anti-gametocyte treatment combined with anti-larval malaria control. Rec Malar Surv Ind. 1934;4:77–94.
61.
Ray AP. Prophylactic use of paludrine in a tea estate. Indian J Malariol. 1948;2:35–66.
62.
Banerjea R. The control of malaria in a rural area of West Bengal. Indian J Malariol. 1949;3:371–86.
63.
Van Goor WT, Lodens JG. Clinical malaria prophylaxis with proguanil. Doc Neerl Indones Morbis Trop. 1950;2:62–81.
64.
Norman T. An investigation of the failure of proguanil prophylaxis. Trans R Soc Trop Med Hyg. 1952;46:653–5.CrossRefPubMed
65.
Archibald HM, Bruce-Chwatt LJ. Suppression of malaria with pyrimethamine in Nigerian school children. Bull World Health Organ. 1956;15:775–84.PubMedPubMedCentral
66.
Clyde DF, Webbe G, Shute GT. Single dose pyrimethamine treatment of Africans during a malaria epidemic in Tanganyika. East Afr Med J. 1958;35:23–9.PubMed
67.
Van Dijk W. Mass chemoprophylaxis with chloroquine additional to DDT indoor spraying. Trop Geogr Med. 1958;10:379–84.
68.
Afridi MK, Rahim A. Further observation on the interruption of malaria transmission with single dose of pyrimethamine (daraprim). Riv Parassitol. 1959;20:229–42.
69.
Van Dijk W. Mass treatment of malaria with chloroquine: results of a trial in Inanwatan. Trop Geogr Med. 1961;13:351–6.PubMed
70.
Metselaar D. Seven years’ malaria research and residual house spraying in Netherlands New Guinea. Am J Trop Med Hyg. 1961;10:327–34.PubMed
71.
Ho C. Studies on malaria in new China. Chin Med J. 1965;84:491–7.PubMed
72.
Ossi GT. An epidemic in the life of a malaria eradication programme. Bull Endem Dis. 1967;9:5–18.
73.
Singh MV, Agarwala RS, Singh KN. Epidemiological study of focal outbreak of malaria in consolidation phase area and evaluation of remedial measures in Uttar Pradesh (India). Bull Ind Soc Mal Com Dis. 1968;5:207–20.
74.
Lakshmanacharyulu T, Guha AK, Kache SR. Control of malaria epidemics in a river valley project. Bull Ind Soc for Mal Com. 1968;5:94–105.
75.
Onori E. Experience with mass drug administration as a supplementary attack measure in areas of vivax malaria. Bull World Health Organ. 1972;47:543–8.PubMedPubMedCentral
76.
Najera JA, Shidrawi GR, Storey J, Lietaert PEA. Mass drug administration and DDT indoor-spraying as antimalarial measures in the northern savanna of Nigeria. Malar Bull World Health Organ. 1973;73:1–34.
77.
Schliessmann DJ, Joseph VR, Solis M, Carmichael GT. Drainage and larviciding for control of a malaria focus in Haiti. Mosq News. 1973;33:371–8.
78.
Paik HY. Problem areas in the malaria eradication programme in the British Solomon Islands. PNG Med J. 1974;17:111–5.
79.
Kondrashin AV, Sanyal MC. Mass drug administration in Andhra Pradesh in areas under Plasmodium falciparum containment programme. J Commun Dis. 1985;17:293–9.PubMed
80.
Strickland GT, Khaliq AA, Sarwar M, Hassan H, Pervez M, Fox E. Effects of Fansidar on chloroquine-resistant Plasmodium falciparum in Pakistan. Am J Trop Med Hyg. 1986;35:61–5.PubMed
81.
Hii JL, Vun YS, Chin KF, Chua R, Tambakau S, Binisol ES, et al. The influence of permethrin-impregnated bednets and mass drug administration on the incidence of Plasmodium falciparum malaria in children in Sabah, Malaysia. Med Vet Entomol. 1987;1:397–407.CrossRefPubMed
82.
Babione RW. Epidemiology of malaria eradication. II. Epidemiology of malaria eradication in Central America: a study of technical problems. Am J Public Health Nations Health. 1966;56:76–90.CrossRefPubMedPubMedCentral
83.
Chaudhuri RN, Janardan Poti S. Suppressive treatment of malaria; with statistical analysis. Indian J Malariol. 1950;4:115–33.PubMed
84.
Edeson JF, Wharton RH, Wilson T, Reid JA. An experiment in the control of rural malaria in Malaya. Med J Malaya. 1957;12:319–47.PubMed
85.
Omer AH. Species prevalence of malaria in northern and southern Sudan, and control by mass chemoprophylaxis. Am J Trop Med Hyg. 1978;27:858–63.PubMed
Metadata
Title
Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review
Authors
Bipin Adhikari
Nicola James
Gretchen Newby
Lorenz von Seidlein
Nicholas J. White
Nicholas P. J. Day
Arjen M. Dondorp
Christopher Pell
Phaik Yeong Cheah
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2016
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-016-1593-y

Other articles of this Issue 1/2016

Malaria Journal 1/2016 Go to the issue

Research

Application of magnetic cytosmear for the estimation of Plasmodium falciparum gametocyte density and detection of asexual stages in asymptomatic children

Research

Immunogenetic markers associated with a naturally acquired humoral immune response against an N-terminal antigen of Plasmodium vivax merozoite surface protein 1 (PvMSP-1)

Research

Facilitating factors and barriers to malaria research utilization for policy development in Malawi

Research

Determinants of prompt and adequate care among presumed malaria cases in a community in eastern Rwanda: a cross sectional study

Research

Malaria in pregnancy: a passive surveillance study of pregnant women in low transmission areas of Colombia, Latin America

Erratum

Erratum to: Glucose-6-phosphate dehydrogenase deficiency prevalence and genetic variants in malaria endemic areas of Colombia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits